-

Cure Rare Disease Acquires Laboratory Space for New Headquarters in Connecticut

Boston-based biotechnology company to relocate headquarters and expand operations in Woodbridge

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a clinical-stage nonprofit biotechnology company, has acquired its first laboratory space at 4 Research Drive in Woodbridge, Connecticut, where the organization will relocate its headquarters and expand its research and development operations.

The 30,000 square foot facility was purchased by CRD to continue its mission of developing therapeutics for rare and ultra-rare neuromuscular diseases through a novel framework. CRD will also make 15,000 square feet of space available for lease to other life science and healthcare firms.

“We are excited to join the Woodbridge and greater New Haven communities to deepen our R&D efforts for rare disease patients while also offering biotechnology companies the opportunity to access Class A life sciences space in the New Haven area,” said CRD Founder and CEO, Rich Horgan.

The space will be extensively renovated through the end of 2022 and into 2023, to improve the exterior, interior and parking lot of the facility. Svigal+Partners will oversee the architectural work associated with the renovations.

These renovations were partially funded by a generous grant from the Health Resources and Services Administration (HRSA), the application for which was championed by United States Senators Richard Blumenthal and Chris Murphy of Connecticut. AdvanceCT, among other nonprofit organizations and local municipalities, offered support of CRD’s proposal to HRSA.

"AdvanceCT is thrilled to welcome Cure Rare Disease to Connecticut,” said Tim Miller, Director of BD, Life Sciences, at AdvanceCT. “As one of our newest entrants to the CT life science ecosystem, CRD is making transformative progress in rare disease R&D - in addition to supporting growth for early-stage companies at their facility. We look forward to supporting them through their development.”

For leasing inquiries, please reach out to Jeff Dow at Dow Realty Co., at 203-776-0000.

ABOUT CURE RARE DISEASE

Cure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Boston, is transforming possibilities for people with rare diseases by developing advanced therapeutics in time to save lives. Through a collaborative community of forward-thinking families, patients, scientists and supporters, Cure Rare Disease has enabled an ecosystem of innovation and discovery to overcome the obstacles inherent in existing models of medicine and to expedite life-saving genetic technologies from research to the clinic. Learn more at www.cureraredisease.org.

Contacts

Media:
Suzanne Day
617-275-6521
media@cureRD.org

Cure Rare Disease

Details
Headquarters: Boston, USA
CEO: Richard Horgan
Employees: 5
Organization: NON

Release Versions

Contacts

Media:
Suzanne Day
617-275-6521
media@cureRD.org

Social Media Profiles
More News From Cure Rare Disease

Cure Rare Disease Awarded $7.4 Million CIRM Grant to Advance Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $7.4 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of a novel gene therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9 (LGMD2i/R9), a progressive neuromuscular disorder with limited treatment options. Cure Rare Disease launched its LGMD2i/R9 program to develop a therapeutic solution for patients suffering from this rare condition. The program, C...

Cure Rare Disease Secures FDA Orphan Drug Designation for Investigational Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a 501(c)(3) nonprofit biotechnology company developing genetic therapies for ultra-rare neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its investigational therapy, CRD-003, for the treatment of congenital muscular dystrophy caused by biallelic mutations in the FKRP gene (Limb-Girdle Muscular Dystrophy Type R9, LGMD2i/R9). The investigational therap...

Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a nonprofit biotechnology organization developing genetic therapies for ultra-rare diseases, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy program for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMDR9). The LGMDR9 program, known as CRD-003, utilizes a novel, liver de-targeting, muscle tropic capsi...
Back to Newsroom